Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations
by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung can
Updated on: September 27,2024
0

Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations
by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung can
Updated on:September 27,2024
0
